|
Market Closed -
Nasdaq
21:00:00 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 25.14 USD | -3.46% |
|
-2.82% | -6.12% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
Company Valuation: Amphastar Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,114 | 1,354 | 2,963 | 1,785 | 1,231 | 1,069 | - | - |
| Change | - | 21.52% | 118.8% | -39.75% | -31.07% | -13.1% | - | - |
| Enterprise Value (EV) 1 | 1,114 | 1,354 | 2,963 | 2,235 | 1,669 | 1,375 | 1,259 | 1,136 |
| Change | - | 21.52% | 118.8% | -24.56% | -25.34% | -17.59% | -8.45% | -9.8% |
| P/E | 18.6x | 16.1x | 23.8x | 12.1x | 13.2x | 11.6x | 9.52x | 10.1x |
| PBR | - | - | - | 2.41x | 1.55x | 1.21x | - | - |
| PEG | - | 0.4x | 0.5x | 0.7x | -0.4x | 1.68x | 0.4x | -1.67x |
| Capitalization / Revenue | 2.55x | 2.71x | 4.6x | 2.44x | 1.71x | 1.43x | 1.36x | 1.32x |
| EV / Revenue | 2.55x | 2.71x | 4.6x | 3.05x | 2.32x | 1.84x | 1.61x | 1.41x |
| EV / EBITDA | 11.2x | 9.21x | 10.4x | 7.18x | 6.74x | 6.46x | 5.94x | 5.47x |
| EV / EBIT | 14.5x | 11.1x | 12.1x | 8.66x | 7.73x | 7.64x | 6.86x | 5.87x |
| EV / FCF | - | 20.8x | - | 13x | 13.8x | 10.3x | 10.9x | 9.23x |
| FCF Yield | - | 4.81% | - | 7.71% | 7.26% | 9.74% | 9.21% | 10.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.25 | 1.74 | 2.6 | 3.06 | 2.03 | 2.17 | 2.64 | 2.48 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 437.8 | 499 | 644.4 | 732 | 719.9 | 747.3 | 784 | 807.7 |
| EBITDA 1 | 99.1 | 147.1 | 283.9 | 311.1 | 247.5 | 212.9 | 212.1 | 207.8 |
| EBIT 1 | 76.9 | 121.8 | 245.8 | 258.2 | 215.9 | 180.1 | 183.7 | 193.5 |
| Net income 1 | 62.12 | 91.39 | 137.5 | 159.5 | 98.09 | 99.32 | 115.4 | 111.1 |
| Net Debt 1 | - | - | - | 450 | 438.3 | 306 | 189.8 | 66.41 |
| Reference price 2 | 23.29 | 28.02 | 61.85 | 37.13 | 26.78 | 25.14 | 25.14 | 25.14 |
| Nbr of stocks (in thousands) | 47,849 | 48,331 | 47,907 | 48,081 | 45,952 | 42,538 | - | - |
| Announcement Date | 10/03/22 | 28/02/23 | 28/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.59x | 1.84x | 6.46x | -.--% | 1.07B | |
| 36.74x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.5x | 18.29x | 2.02% | 636B | |
| 36.46x | 8.38x | 17.29x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.67x | 13.94x | 2.81% | 295B | |
| 22.42x | 4.53x | 12.96x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 27.67x | 6.52x | 17.47x | 1.9% | 400.54B | |
| Weighted average by Cap. | 35.13x | 8.29x | 20.39x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMPH Stock
- Valuation Amphastar Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
